Haleon PLC Executes Share Buyback to Strengthen Capital Structure

Haleon PLC ( (GB:HLN) ) has issued an announcement.

Haleon PLC announced the purchase and cancellation of 816,897 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of a strategic move to optimize the company’s capital structure, potentially enhancing shareholder value and reflecting confidence in its long-term growth prospects.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £340.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on GB:HLN Stock

According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.

Haleon PLC’s strong financial health, strategic growth initiatives, and positive market momentum contribute to a robust stock outlook. While valuation metrics suggest caution due to higher P/E and modest dividend yield, the company’s strategic focus on innovation and market expansion, supported by recent corporate activities, reinforces investor confidence despite external challenges like currency fluctuations.

To see Spark’s full report on GB:HLN stock, click here.

More about Haleon PLC

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its well-known brands, such as Advil, Centrum, and Sensodyne, are grounded in trusted science and innovation.

Average Trading Volume: 28,117,257

Technical Sentiment Signal: Buy

Current Market Cap: £36.55B

For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.